CoChat

A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target

Open access
Freeman, Zachary T., Nirschl, Thomas R., Hovelson, Daniel H., Johnston, Robert J., Engelhardt, John J., Selby, Mark J., Kochel, Christina M., Lan, Ruth Y., Zhai, Jingyi, Ghasemzadeh, Ali, Gupta, Anuj, Skaist, Alyza M., Wheelan, Sarah J., Jiang, Hui, Pearson, Alexander T., Snyder, Linda A., Korman, Alan J., Tomlins, Scott A., Yegnasubramanian, Srinivasan, Drake, Charles G. · 2020 · Journal of Clinical Investigation
Cited by 124

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Despite advancements in targeting the immune checkpoints program cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) for cancer immunotherapy, a large number of patients and cancer types remain unresponsive. Current immunotherapies focus on modulating an antitumor immune response by directly or indirectly expanding antitumor CD8 T cells. A complementary strategy might involve inhibition of Tregs that otherwise suppress antitumor immune responses. Here, we sought to identify functional immune molecules preferentially expressed on tumor-infiltrating Tregs. Using genome-wide RNA-Seq analysis of purified Tregs sorted from multiple human cancer types, we identified a conserved Treg immune checkpoint signature. Using immunocompetent murine tumor models, we found that antibody-mediated depletion of 4-1BB-expressing cells (4-1BB is also known as TNFRSF9 or CD137) decreased tumor growth without negatively affecting CD8 T cell function. Furthermore, we found that the immune checkpoint 4-1BB had a high selectivity for human tumor Tregs and was associated with worse survival outcomes in patients with multiple tumor types. Thus, antibody-mediated depletion of 4-1BB-expressing Tregs represents a strategy with potential activity across cancer types.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci128672

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 124

Metadata

Authors
Freeman, Z. T., Nirschl, T. R., Hovelson, D. H., Johnston, R. J., Engelhardt, J. J., Selby, M. J., Kochel, C. M., Lan, R. Y., Zhai, J., Ghasemzadeh, A., Gupta, A., Skaist, A. M., Wheelan, S. J., Jiang, H., Pearson, A. T., Snyder, L. A., Korman, A. J., Tomlins, S. A., Yegnasubramanian, S., & Drake, C. G.
Venue
Journal of Clinical Investigation
Published
2020-02-04
Volume
130
Issue
3
Pages
1405-1416
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W3005081774
Cited by
124
References
15
FWCI
5.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. https://app.cochat.ai/papers/10.1172/jci128672
The paper
Freeman, Z. T., Nirschl, T. R., Hovelson, D. H., Johnston, R. J., Engelhardt, J. J., Selby, M. J., Kochel, C. M., Lan, R. Y., Zhai, J., Ghasemzadeh, A., Gupta, A., Skaist, A. M., Wheelan, S. J., Jiang, H., Pearson, A. T., Snyder, L. A., Korman, A. J., Tomlins, S. A., Yegnasubramanian, S., & Drake, C. G. (2020). A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. Journal of Clinical Investigation. https://doi.org/10.1172/jci128672

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.